➡️Opdualag (nivolumab and relatlimab-rmbw) Injection

Date of Approval: March 18, 2022
Company: Bristol Myers Squibb
Treatment for: Melanoma

Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.

https://news.1rj.ru/str/ppdprogram

➡️Pluvicto (lutetium lu 177 vipivotide tetraxetan) Injection

Date of Approval: March 23, 2022
Company: Novartis
Treatment for: Prostate Cancer

Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

https://news.1rj.ru/str/ppdprogram

➡️Hyftor (sirolimus) Topical Gel

Date of Approval: March 22, 2022
Company: Nobelpharma America, LLC
Treatment for: Facial Angiofibroma Associated with Tuberous Sclerosis

Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Nasonex 24HR Allergy (mometasone furoate monohydrate) Nasal Spray

Date of Approval: March 17, 2022
Company: Perrigo Company plc
Treatment for: Allergic Rhinitis

Nasonex 24HR Allergy (mometasone furoate monohydrate) is a corticosteroid nasal spray available over-the-counter for the temporary relief of the symptoms of hayfever or other upper respiratory allergies.

https://news.1rj.ru/str/ppdprogram

➡️Zegalogue (dasiglucagon) Injection

Date of Approval: March 22, 2021
Company: Zealand Pharma A/S
Treatment for: Hypoglycemia

Zegalogue (dasiglucagon) is a glucagon analog antihypoglycemic agent for the treatment of severe hypoglycemia in diabetes patients aged 6 years and older.

https://news.1rj.ru/str/ppdprogram

➡️Lybalvi (olanzapine and samidorphan) Tablets

Date of Approval: May 28, 2021
Company: Alkermes plc
Treatment for: Schizophrenia, Bipolar Disorder

Lybalvi (olanzapine and samidorphan) is a combination of an established antipsychotic agent (olanzapine) and a novel μ-opioid receptor antagonist (samidorphan) for the treatment of schizophrenia and bipolar I disorder.

https://news.1rj.ru/str/ppdprogram

➡️Astepro Allergy (azelastine) Nasal Spray

Date of Approval: June 17, 2021
Company: Bayer HealthCare LLC
Treatment for: Allergic Rhinitis

Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

https://news.1rj.ru/str/ppdprogram

➡️Wegovy (semaglutide) Injection

Date of Approval: June 4, 2021
Company: Novo Nordisk
Treatment for: Obesity

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).

https://news.1rj.ru/str/ppdprogram

➡️Soaanz (torsemide) Tablets

Date of Approval: June 14, 2021
Company: Sarfez Pharmaceuticals
Treatment for: Edema

Soaanz (torsemide) is a loop diuretic indicated for the treatment of edema associated with heart failure or renal disease in adults.

https://news.1rj.ru/str/ppdprogram

➡️Verkazia (cyclosporine) Ophthalmic Emulsion

Date of Approval: June 23, 2021
Company: Santen Inc.
Treatment for: Vernal Keratoconjunctivitis

Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

https://news.1rj.ru/str/ppdprogram

➡️Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection

Date of Approval: June 30, 2021
Company: Jazz Pharmaceuticals plc
Treatment for: Acute Lymphoblastic Leukemia

Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).

https://news.1rj.ru/str/ppdprogram

➡️Kerendia (finerenone) Tablets

Date of Approval: July 9, 2021
Company: Bayer
Treatment for: Chronic Kidney Disease Associated with Type 2 Diabetes

Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

https://news.1rj.ru/str/ppdprogram

➡️(fexinidazole) Tablets

Date of Approval: July 16, 2021
Company: Drugs for Neglected Diseases Initiative
Treatment for: Trypanosomiasis

Fexinidazole is a nitroimidazole antibacterial indicated for the treatment of human African trypanosomiasis (African sleeping sickness) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.

https://news.1rj.ru/str/ppdprogram

➡️Bylvay (odevixibat) Capsules

Date of Approval: July 20, 2021
Company: Albireo Pharma, Inc.
Treatment for: Progressive Familial Intrahepatic Cholestasis (PFIC)

Bylvay (odevixibat) is an ileal bile acid transport (IBAT) inhibitor for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).

https://news.1rj.ru/str/ppdprogram

➡️Twyneo (tretinoin and benzoyl peroxide) Cream

Date of Approval: July 26, 2021
Company: Sol-Gel Technologies, Ltd.
Treatment for: Acne

Twyneo (tretinoin and benzoyl peroxide) is a topical retinoid and antibacterial fixed-dose combination for the treatment of acne vulgaris in adults and children 9 years of age and older.

https://news.1rj.ru/str/ppdprogram

➡️Korsuva (difelikefalin) Injection

Date of Approval: August 23, 2021
Company: Cara Therapeutics, Inc.
Treatment for: Chronic Kidney Disease-Associated Pruritus

Korsuva (difelikefalin) is a selective peripheral kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

https://news.1rj.ru/str/ppdprogram

➡️Skytrofa (lonapegsomatropin-tcgd) for Injection

Date of Approval: August 25, 2021
Company: Ascendis Pharma A/S
Treatment for: Pediatric Growth Hormone Deficiency

Skytrofa (lonapegsomatropin-tcgd) is a human growth hormone used once-weekly for the treatment of pediatric growth hormone deficiency.

https://news.1rj.ru/str/ppdprogram

➡️Trudhesa (dihydroergotamine mesylate) Nasal Spray

Date of Approval: September 2, 2021
Company: Impel NeuroPharma, Inc.
Treatment for: Migraine

Trudhesa (dihydroergotamine mesylate) is a nasally administered dihydroergotamine (DHE) formulation for the acute treatment of migraine with or without aura in adults.

https://news.1rj.ru/str/ppdprogram

➡️Tivdak (tisotumab vedotin-tftv) Lyophilized Powder for Injection

Date of Approval: September 20, 2021
Company: Seagen Inc.
Treatment for: Cervical Cancer

Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody and microtubule inhibitor conjugate for the treatment of patients with recurrent or metastatic cervical cancer.

https://news.1rj.ru/str/ppdprogram

➡️Opzelura (ruxolitinib) Cream

Date of Approval: September 21, 2021
Company: Incyte
Treatment for: Atopic Dermatitis

Opzelura (ruxolitinib) cream is a topical Janus kinase (JAK) inhibitor used for the treatment of atopic dermatitis.

https://news.1rj.ru/str/ppdprogram

➡️Qulipta (atogepant) Tablets

Date of Approval: September 28, 2021
Company: AbbVie Inc.
Treatment for: Migraine Prevention

Qulipta (atogepant) is an oral, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults.

https://news.1rj.ru/str/ppdprogram